摘要
目的 探讨膦甲酸钠(可耐)治疗慢性乙型肝炎的近期疗效及毒副作用。方法 选择慢性乙型肝炎46例,随机分为2组,对照组13例仅给予常规护肝药物,治疗组33例在对照组治疗基础上加用膦甲酸钠,疗程28 d。治疗前后检测肝功能、乙肝病毒标志物和乙肝病毒DNA,同时观察患者症状、体征的改变及药物的不良反应。结果 治疗组HBV-DNA平均值由(5.95±4.45)×10 copies·mL-1下降至(3.05±4.14)×105copies·mL-1(P<0.05),对照组HBV-DNA平均值由(7.66±7.21)×105 copies·mL-1下降为(6.40±7.54)×105 copies·mL-1(P>0.05);治疗组、对照组HBeAg阴转率分别为6/20(30％)、2/10(20％) (P>0.05);治疗组的ALT、 SB、TBA在治疗前后有显著性差异(P<0.05),对照组仅ALT治疗前后有显著性差异(P<0.05)。在治疗过程中未发生严重不良反应。结论 短期静脉注射膦甲酸钠具有较好的抑制乙型肝炎病毒复制的效果,同时有助于改善肝功能,远期疗效有待追踪观察。
OBJECTIVE To determine the short-term efficacy and safety of foscarnet sodium in the treatment of chronic hepatitis B. METHODS Fourty-six patients with chronic hepatitis B were randomly divided, who received only liver-protective drugs (n=13) or foscarnet sodium plus liver-protective drugs (n = 33) for 28 d. Liver function, the level of serum HBV-DNA, and HBV markers were measured hefore and after the treatment. Side effects and changes were observed. RESULTS The mean serum HBV-DNA level of the treatment group decreased from (5.95±4.45)×105 copies·mL-1 to (3. 05±4. 14) ×105 copies·mL-1 (P<0. 05) and that of the control group decreased from (7. 66±7. 21)×102 copies·mL-1 to (6. 40±7. 54)×105 copies·mL-1 (P>0. 05) . The negative turn over rate of HBeAg of the treatment group and the control group were 30% and 20% respectively (P>0. 05) . The ALT, SB. and TBA of the treatment group decreased obviously after the treatment (P<0. 05) . There were no severe side effects in the treatment. CONCLUSIONS Short-term infusion of foscarnet sodium can inhibit HBV replication and improve the liver function, yet its long-term efficacy needs to be further investigated.
出处
《中南药学》
CAS
2003年第4期239-241,共3页
Central South Pharmacy
